The immune system as the sixth sense

Journal of Internal Medicine

Volumn 257, Issue 2, 2005, Pages 126-138

  Blalock, J Edwin ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Immune neuroendocrine interactions; Immunosensor; Interferon alpha; Neuropeptides; Neurotransmitter receptors

Indexed keywords

CYTOKINE; LIGAND; NEUROTRANSMITTER;

CONFERENCE PAPER; IMMUNE SYSTEM; IMMUNOREGULATION; IMMUNOSENSOR; INFECTION; INFLAMMATION; NERVOUS SYSTEM; NEUROTRANSMISSION; PRIORITY JOURNAL; STRESS;

ANIMALS; CYTOKINES; HUMANS; IMMUNE SYSTEM; MICE; MODELS, IMMUNOLOGICAL; NEUROIMMUNOMODULATION; NEUROTRANSMITTER AGENTS; PLACEBOS; RECEPTORS, NEUROTRANSMITTER; SENSATION;

EID: 13244292487     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2004.01441.x     Document Type: Conference Paper

References (99)

1. Blalock JE. The immune system as a sensory organ. J Immunol 1984; 132: 1067-70.
2. Blalock JE. Relationships between neuroendocrine hormones and lymphokines. In: Pick E, ed. Lymphokines. pp. 1-13. Orlando, FL: Academic Press, 1984.
3. Woloski BM, Smith EM, Meyer WJ, Fuller GM, Blalock JE. Corticotropin-releasing activity of monokines. Science 1985; 230: 1035-7.
4. Blalock JE, Smith EM. Human leukocyte interferon: structural and biological relatedness to adrenocorticotropic hormone and endorphins. Proc Natl Acad Sci U S A 1980; 77: 5972-4.
5. Smith EM, Blalock JE. Human lymphocyte production of corticotropin and endorphin-like substances: association with leukocyte interferon. Proc Natl Acad Sci U S A 1981; 78: 7530-4.
6. Epstein LB, Rose ME, McManus NH, Li CH. Absence of functional and structural homology of natural and recombinant human leukocyte interferon (IFN-alpha) with human alpha-ACTH and beta-endorphin. Biochem Biophy Res Commun 1982; 104: 341-6.
7. Lyons PD, Blalock JE. Pro-opiomelanocortin gene expression and protein processing in rat mononuclear leukocytes. J Neuroimmunol 1997; 78: 47-56.
8. Menzies R, Patel R, Hall NRS, O'Grady MP, Rier SE. Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes. Life Sci 1992; 50: PL227-32.
9. Blalock JE, Smith EM. Human leukocyte interferon (HuIFN-alpha): potent endorphin-like opioid activity. Biochem Biophys Res Commun 1981; 101: 472-8.
10. Jiang CL, Song LX, Lu CL et al. Analgesic effect of interferon-alpha via mu opioid receptor in the rat. Neurochem Int 2000; 36: 193-6.
11. Wang YX, Jiang CL, Lu CL et al. Distinct domains of IFNα mediate immune and analgesic effects respectively. J Neuroimmunol 2000; 108: 64-7.
12. Kavelaars A, Ballieux RE, Heijnen CJ. The role of IL-1 in the corticotropin-releasing factor and arginine-vasopressin-induced secretion of immunoreactive beta-endorphin by human peripheral blood mononuclear cells. J Immunol 1989; 142: 2338-42.
13. Westly HJ, Kleiss AJ, Kelley KW, Wong PK, Yuen PH. Newcastle disease virus-infected splenocytes express the proopiomelanocortin gene. J Exp Med 1986; 163: 1589-94.
14. Lolait SJ, Clements JA, Markwick AJ et al. Pro-opiomelanocortin messenger ribonucleic acid and posttranslational processing of beta endorphin in spleen macrophages. J Clin Invest 1986; 77: 1776-9.
15. Gates EL, Allaway GP, Armstrong GR, Boyajian RA, Kehrl JH, Prabhakar BS. Human lymphocytes produce pro-opiomelanocortin gene-related transcripts. Effects of lymphotropic viruses. J Biol Chem 1988; 263: 10041-4.
16. Buzzetti R, McLoughlin L, Lavender PM, Clark AJ, Rees LH. Expression of pro-opiomelanocortin gene and quantification of adrenocorticotropic hormone-like immunoreactivity in human normal peripheral mononuclear cells and lymphoid and myeloid malignancies. J Clin Invest 1989; 83: 733-7.
17. Bloom FE. Molecular markers of neuronal specificity. In: Wong F, Eaton DC, Konkel DA, Perez-Pola JR, eds. Molecular Neruoscience: Expression of Neural Genes, pp. 1-10. New York, NY; Alan R. Liss, 1987.
18. Smith EM, Galin FS, LeBoeuf RD, Coppenhaver DH, Harbour DV, Blalock JE. Nucleotide and amino acid sequence of lymphocyte-derived corticotropin: endotoxin induction of a truncated peptide. Proc Natl Acad Sci USA 1990; 87: 1057-60.
19. Galin FS, LeBoeuf RD, Blalock JE. A lymphocyte mRNA encodes the adrenocorticotropin/β-lipotropin region of the pro-opiomelanocortin gene. Prog Neuroendocr Immunol 1990; 3: 205-208.
20. Galin FS, LeBoeuf RD, Blalock JE. Corticotropin-releasing factor upregulates expression of two truncated pro-opiomelanocortin transcripts in murine lymphocytes. J Neuroimmunol 1991; 31: 51-8.
21. Blalock JE. The syntax of immune-neuroendocrine communication. Immunol Today 1994; 15: 504-11.
22. Tayebati SK, El-Assouad D, Ricci A, Amenta F. Immunochemical and immunocytochemical characterization of cholinergic markers in human peripheral blood lymphocytes. J Neuroimmunol 2002; 132: 147-55.
23. Warthan MD, Freeman J, Loesser K et al. Phenylethanolamine N-methyl transferase expression in mouse thymus and spleen. Brain Behav Immun 2002; 16: 493-9.
24. Carrillo-Vico A, Calvo JR, Abreu P et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18: 537-9.
25. Seale JV, Jessop DS, Harbuz MS. Immunohistochemical staining of endomorphin 1 and 2 in the immune cells of the spleen. Peptides 2004; 25: 9-14.
26. Breder CD, Dinarello CA, Saper CB. Interleukin 1 immunoreacative innervation of the human hypothalamus. Science 1988; 240: 321-4.
27. Wybran J, Appelboom T, Famaey JP, Govaerts A. Suggestive evidence for receptors for morphine and methionine-enkephalin on normal human blood T lymphocytes. J Immunol 1979; 123: 1068-70.
28. McDonough RJ, Madden JJ, Falek A et al. Alteration of T and null lymphocyte frequencies in the peripheral blood of human opiate addicts: in vivo evidence for opiate receptor sites on T lymphocytes. J Immunol 1980; 125: 2539-43.
29. Johnson HM, Smith EM, Torres BA, Blalock JE. Neuroendocrine hormone regulation of in vitro antibody formation. Proc Natl Acad Sci U S A 1982; 79: 4171-4.
30. Carr DJ, Kim CH, de Costa B, Jacobson AE, Rice KC, Blalock JE. Evidence for a delta-class opioid receptor on cells of the immune system. Cell Immunol 1988; 116: 44-51.
31. Carr DJ, DeCosta BR, Kim CH et al. Opioid receptors on cells of the immune system: evidence for delta- and kappa-classes. J Endocrinol 1989; 122: 161-8.
32. Carr DJ, DeCosta BR, Jacobson AE, Rice KC, Blalock JE. Enantioselective kappa opioid binding sites on the macrophage cell line, P388d1. Life Sci 1991; 49: 45-51.
33. Kieffer BL, Befort K, Gaveriaux-Ruff C, Hirth CG. The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci USA 1992; 89: 12048-52.
34. Evans CJ, Keith D, Magendzo K, Morrison H, Edwards RH. Cloning of a delta opioid receptor by functional expression. Science 1992; 258: 1952-5.
35. Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, Reisine T, Bell GL. Cloning and functional comparison of κ and δ opioid receptors from mouse brain. Proc Natl Acad Sci U S A 1993; 90: 6736-40.
36. Thompson RC, Mansour A, Akil H, Watson SJ. Cloning and pharmacological characterization of a rat μ opioid receptor. Neuron 1993; 11: 903-13.
37. Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, Uhl GR. μ Opiate receptor: cDNA cloning and expression. Proc Natl Acad Sci USA 1993; 90: 10230-4.
38. Joseph DB, Bidlack JM. The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line down-regulates regulatory protein. J Pharmacol Exp Ther 1995; 272: 970-6.
39. Lawrence DM, Bidlack JM. The kappa opioid receptor expressed on hte mouse R1.1 thymoma cell line is coupled to adenyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J Pharmacol Exp Ther 1993; 266: 1678-83.
40. Sedqi M, Roy S, Ramakrishnan S, Loh HH. Expression cloning of a full-length cDNA encoding delta opioid receptor from mouse thymocytes. J Neuroimmunol 1996; 65: 167-70.
41. Halford WP, Gebhardt BM, Carr DJJ. Functional role and sequence analysis of a lymphocyte orphan opioid receptor. J Neuroimmunol 1996; 59: 91-101.
42. Carr DJJ, Rogers TJ, Weber RJ. The relevance of opioids and opioid receptors on immunocompetence and immune homeostasis. Proc Soc Exp Biol Med 1996; 113: 248-57.
43. Meunier JC, Mollereau C, Toll L et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature 1995; 377: 532-5.
44. Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Orphanin FQ. A neuropeptide that activates an opioidlike G protein-coupled erceptor. Science 1995; 270: 792-4.
45. Wick MJ, Minnerath SR, Roy S, Ramkrishnan S, Loh HH. Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines. Mol Brain Res 1995; 32: 342-7.
46. Alvarez-Mon A, Kehrl JH, Fauci AS. A potential role for adrenocorticotropin in regulating human B lymphocyte functions. J Immunol 1985; 135: 3823-6.
47. Brooks KH. Adrenocorticotropin (ACTH) functions as a late-acting B cell growth factor and synergizes with interleukin 5. J Mol Cell Immunol 1990; 4: 327-35.
48. Bost KL, Clarke BL, Xu J, Kiyono H, McGhee JR, Pascual D. Modulation of IgM secretion and H chain mRNA expression in CH12.LX.C4.5F5 B cells by adrenocorticotropic hormone. J Immunol 1990; 145: 4326-31.
49. Johnson HM, Torres BA, Smith EM, Dion LD, Blalock JE. Regulation of lymphokine (gamma-interferon) production by corticotropin. J Immunol 1984; 132: 246-50.
50. Clarke BL, Bost KL. Differential expression of functional adrenocorticotropic hormone receptors by subpopulations of lymphocytes. J Immunol 1989; 143: 464-9.
51. Smith EM, Brosnan P, Meyer WJ, Blalock JE. An ACTH receptor on human mononuclear leukocytes. Relation to adrenal ACTH-receptor activity. N Engl J Med 1987; 317: 1266-9.
52. Weigent DA, Blalock JE. Neuroimmunoendocrinology. In: Nijkamp FP, Parnham MJ, eds. Principles of Immunopharmacology. Basel. Switzerland: Birkhauser Verlag, 2005 (in press).
53. Metal'nikov S, Chorine V. Role des reflexes conditionnels dans l'immunite. Annales de l'Institute Pasteur 1926; 40: 893-900.
54. Ader R, Cohen N. The influence of conditioning on immune responses. In: Ader R, Feiten DL, Cohen N, eds. Psychoneuroimmunology, pp. 611-646. San Diego, CA: Academic Press. 1991.
55. Keller SE, Schleifer SJ, Demetrikopoulos MK. Stress-induced changes in immune function in animals: hypothalamo-pituitary-adrenal influences. In: Ader R, Feiten DL, Cohen N, eds. Psychoneuroimmunology, pp. 771-787. San Diego, CA: Academic Press, 1991.
56. Kavelaars A, Heijnen CJ, Tennckcs R, Bruggink JE, Koolhaas JM. Individual behavioral characteristics of wild-type rats predict susceptibility to experimental autoimmune encephalomyelitis. Brain Behav Immun 1999; 13: 279-86.
57. Feiten DL, Cohen N, Ader R, Feiten SY, Carlson SL, Roszman TL. Central neural circuits involved in neural-immune interactions. In: Ader R, Feiten DL, Cohen N, eds. Psychoneuroimmunology, pp. 3-25. San Diego, CA: Academic Press, 1991.
58. Besedovsky HO, Sorkin E, Felix D, Haas H. Hypothalamic changes during the immune response. Eur J Immunol 1977; 7: 323-5.
59. Stevens-Felten SY, Bellinger DL. Noradrenergic and peptidergic innervation of lymphoid organs. In: Blalock JE, ed. Neuroimmunoendocrinology, pp. 99-31. Basel. Switzerland: Karger AG, 1997.
60. Blalock JE. A molecular basis for bidirectional communication between the immune and neuroendocrine systems. Physiol Rev 1989; 69: 1-32.
61. Blalock JE. The immune system: our sixth sense. Immunologist 1994; 2: 8-15.
62. Watkins LR, Maier SF. Implications of immune-to-brain communication for sickness and pain. Proc Natl Acad Sci U S A 1999; 96: 7710-3.
63. Laye S, Bluthe RM, Kent S et al. Subdiaphragmatic vagotomy blocks induction of IL-1β mRNA in mice brain in response to peripheral LPS. Am J Physiol 1995; 268: R1327-31.
64. Machelska H, Stein C. Pain control by immune-derived opioids. Clin Exp Pharmacol Physiol 2000; 27: 533-6.
65. Sternberg EM. Neural-immune interactions in health and disease. J Clin Invest 1997; 100: 2641-7.
66. Borovikova LV, Ivanova S, Zhang M et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000; 405: 458-62.
67. Sato KZ, Fujii T, Watanabe Y et al. Diversity of mRNA expression for muscarinic acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. Neurosci Lett 1999; 266: 17-20.
68. Wang H, Yu M, Olchani M et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003; 421: 384-8.
69. Fujii T, Yamada S, Watanabe Y et el. Constitutive expression of mRNA for the same choline acetyltransferase as that in the nervous system, an acetylcholine-synthesizing enzyme, in human leukemic T-cell lines. Neurosci Lett 1999; 259: 71-4.
70. Kawashima K, Fujii T, Watanabe Y, Misawa H. Synthesis of acetylcholine and expression of mRNA for muscarinic receptor subtypes in T-lymphocytes. Life Sci 1998; 62: 1701-5.
71. Jerne NK. The generative grammar of the immune system. Science 1985; 229: 1057-9.
72. Davis MM. Panning for T-cell gold. The Scientist 2004; 18: 28-9.
73. Nakashima T, Murakami T, Murai Y, Hori T, Miyata S, Kiyohara T. Naloxone suppresses the rising phase of fever induced by interferon-α. Brain Res Bull 1995; 37: 61-6.
74. Leist M, Ghezzi P, Grasso G et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
75. Arakawa K, Akami T, Okamoto M, Oka T, Nagase H, Matsumoto S. The immunosuppressive effect of δ-opioid receptor antagonist on rat renal allograft survival. Transplantation 1992; 53: 951-3.
76. Tracey KJ. The inflammatory reflex. Nature 2002; 420: 853-9.
77. DeGiorgio CM, Schachter SC, Handforth A et al. Prospective long-term study of vagus nerve stimulation for the treatment of refractory seizures. Epilepsia 2000; 41: 1195-2000.
78. Bernik TR, Friedman SG, Ochani M et al. Systemic anti-inflammatory action of CNI-1493 mediated by the cholinergic anti-inflammatory pathway. J Exp Med 2002; 195: 781-8.
79. Blalock JE. Harnessing a neural-immune circuit to control inflammation and shock. J Exp Med 2002; 195: F25-8.
80. Pullan RD, Rhodes J, Ganesh S et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 811-5.
81. Delgado-Hernandez R, Demitri MT, Carlin A et al. Inhibition of systemic inflammation by central action of the neuropeptide α-melanocyte stimulating hormone. Neuroimmunomodulation 1999; 6: 187-92.
82. Catania A, Arnold J, Macaluso A, Hiltz ME, Lipton JM. Inhibition of acute inflammation in the periphery by central action of salicylates. Proc Natl Acad Sci U S A 1991; 88: 8544-7.
83. Yamamoto Y, Kawaida Y, Noda M et al. Siblings with ACTH insensitivity due to lack of ACTH binding to the receptor. Endocrine J 1995; 42: 171-7.
84. Payne LC, Weigent DA, Blalock JE. Induction of pituitary sensitivity to interleukin-1: a new function for corticotropin-releasing hormone. Biochem Biophy Res Commun 1994; 198: 480-4.
85. Bernton EW, Beach JE, Holaday JW, Smallridge RC, Fein HG. Release of multiple hormones by a direct action of interleukin-1 on pituitary cells. Science 1987; 238: 519-22.
86. Malarkey WB, Zvara BJ. Interleukin-1 beta and other cytokines stimulate adrenocorticotropin release from cultured pituitary cells of patients with Cushing's disease. J Clin Endocrinol Metab 1989; 69: 196-9.
87. Kehrer P, Turnill D, Dayer JM, Muller AF, Gaillard RC. Human recombinant interleukin-1 beta and -alpha, but not recombinant tumor necrosis factor alpha stimulate ACTH release from rat anterior pituitary cells in vitro in a prostaglandin E2 and cAMP independent manner. Neuroendocrinology 1988; 48: 160-6.
88. Fagarasan MO, Eskay R, Axelrod J. Interleukin 1 potentiates the secretion of beta-endorphin induced by secretatogues in a mouse pituitary cell line (AtT-20). Proc Natl Acad Sci U S A 1989; 86: 2070-3.
89. Fagarasan MO, Aiello F, Muegge K, Durum S, Axelrod J. Interleukin 1 induces beta-endorphin secretion via Fos and Jun in AtT-20 pituitary cells. Proc Natl Acad Sci USA 1990; 87: 7871-4.
90. Cambronero JC, Rivas FJ, Borrell J, Guaza C. Interleukin-1-beta induces pituitary adrenocorticotropin secretion: evidence for glucocorticoid modulation. Neuroendocrinology 1992; 55: 648-54.
91. Lumpkin MD. The regulation of ACTH secretion by IL-1. Science 1987; 238: 452-4.
92. Sapolsky R, Rivier C, Yamamoto G, Plotsky P, Vale W. Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science 1987; 238: 522-4.
93. Berkenbosch F, Van Oers J, Del Rey A, Tilders F, Besedovsky H. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 1987; 238: 524-6.
94. Uehara A, Gottschall PE, Dahl RR, Arimura A. Interleukin-1 stimulatse ACTH release by an indirect action which requires endogenous corticotropin releasing factor. Endocrinology 1987; 121: 1580-2.
95. Suda T, Tozawa F, Ishiyama T, Sumitomo T, Yamada M, Demura H. Interleukin-1 stimulates corticotropin-releasing factor gene expression in rat hypothalamus. Endocrinology 1990; 126: 1223-8.
96. Ban E, Milon G, Prudhomme N, Pillion G, Haour F. Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus. Neuroscience 1991; 43: 21-30.
97. Cunningham ET, Jr, Wada E, Carter L, Tracey DE, Battey JF, DeSouza EB. In situ histochemical localization of type 1 interleukin-1 receptor messenger RNA in the central nervous system, pituitary, and adrenal gland of the mouse. J Neurosci 1992; 12: 1101-14.
98. Webster EL, Tracey DE, DeSouza EB. Upregulation of interleukin-1 receptors in mouse AtT-20 pituitary tumor cells following treatment with corticotropin-releasing factor. Endocrinology 1991; 129: 2796-8.
99. Rivier J, Rivier C, Vale W. Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science 1984; 224: 889-91.